Tag: GW Pharmaceuticals PLC- ADR

  • Drug Manufacturers: Neurocrine Biosciences, Inc. (NASDAQ:NBIX), NanoViricides Inc (NYSEMKT:NNVC), GW Pharmaceuticals (NASDAQ:GWPH), Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

    Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced that the Company will report its fourth quarter and year-end 2013 financial results after the Nasdaq market closes on Thursday, February 6, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, February 6, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock opened at $17.00 in last trading session, and closed at $17.19, trading in the range of $16.49 – $17.40. The stock showed a positive/negative weekly performance of -3.48%.

    NanoViricides Inc (NYSEMKT:NNVC) reported that it has signed a “confidential disclosure agreement” (“CDA”) with Viroclinics Biosciences BV (“Viroclinics”) a spinoff of the Department of Viroscience at the Erasmus Medical Centre (“Erasmus”) in Rotterdam the Netherlands. The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides®such as FluCide™ against viruses of mutual interest to both organizations. NanoViricides Inc (NYSEMKT:NNVC) shares closed at $4.65 on last trade day, by gaining 5.20%. Stock 52 week range is $1.12 – $7.59. Company’s market capitalization is $250.43 billion.

    GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the first quarter ended 31 December 2013. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) stock climbed 7.55% and finished the last session at $59.57. The EPS of the stock remained -0.60. Company’s market capitalization is $662.07 billion.

    Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “outperform” rating reiterated by research analysts at BMO Capital Markets in a report released on Monday, American Banking and Market News reports. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) stock opened at $290.6 in last trading session and closed at $302.54. The 52 week range of the stock is $30.38 – $497.00 and the day range was $286.51 – $306.00.